NTRA — Natera, Inc.
$403.95+0.64%
Last close: · regular session
Last 60 sessions
NTRA closed at $403.95 (+0.64%) on Oct 23, 2026. Active automatic shelf (S-3ASR, Dec 2025). Float: 135.2M shares. Latest SEC filing: 4 on Oct 24, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NTRA in the TickerWise workspace.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 4,424
- Website: https://www.natera.com
Latest SEC filings for NTRA
Latest NTRA news
- Natera Partners With TransCode to Advance Colorectal Cancer Trial Read article
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer Read article
- FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay Read article
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma Read article
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer Read article
- Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades' Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.